FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP 1s : r tirzepatidecompound The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Valor Compounding Pharmacy Inc. Berkeley, CA. Untitled Letter issued 03 23 2023 The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide